USA |NASDAQ |USD
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
|Public Float||127.26M||P/E Ratio||-|
|% Short of Float||-||Dividend (Yield)||-|
|Held by Insiders||9.22%||Ex-Dividend Date|
|Held by Institutions||25.69%||IPO Date||Jun 18, 2021|
|Dec 20||Dec 19|
|Sep 21||Jun 21||Mar 21|
Last quarter (ended on September 30 ,2021) Atai life sciences generated a net income of $-31.16M, representing a 167.01% increase compared to the same quarter a year before (ended on September 30 ,2020).
Last fiscal year (ended on December 31 ,2020) Atai life sciences generated a net income of $-169.84M, representing a 1101.32% increase compare to the previous fiscal year (ended on December 31 ,2019).
View More Details on Atai life sciences's “Financials” Section
For the last quarterly earnings period (ended on September 30, 2021) ATAI reported $-0.21 EPS for the quarter, beating the average analysts’ forecasts of $-0.22 EPS by $0.01 (6.54%).
View More Details on Atai life sciences's 'Earnings' Section
Atai life sciences trades on the NASDAQ stock market in USA under the ticker symbol "ATAI". Atai life sciences’s stock symbol can also be displayed as "NASDAQ:ATAI".
Atai life sciences (NASDAQ:ATAI) is owned by 25.69% institutional shareholders and by 9.22% insiders. The rest is owned by the public.
Explore More Details on Atai life sciences's “Ownership” Section
Atai life sciences's key executive team includes the following managers:
Atai life sciences (NASDAQ:ATAI) is classified under the "Healthcare" sector and under the "Biotechnology" industry.
Currently the number of employees working for Atai life sciences is 35.
Atai life sciences (NASDAQ:ATAI) is headquartered in Germany.
Atai life sciences’s mailing address is Krausenstrasse 9-10, Berlin, Germany, 10117.
The company’s phone number is 49 89 2153 9035.